Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s advanced therapies

Tuesday 18th May 2021

08:00 PDT; 11:00 EDT; 16:00 BST; 17:00 CEST 

Now that mRNA-based vaccines and gene therapies have been proven, how do we as an industry take the next step? How do we produce the large quantities of high-quality viral vectors and plasmids needed to propel other candidates forward? Innovation has a key role to play. Here we’ll describe modern purification technology for plasmid DNA and adeno-associated virus (AAV) that’s poised to improve productivity and speed in both processes. We’ll compare this new tech with legacy methods to show what’s possible.

In this webinar, you will learn about:

  • Strategies to increase capacity and flexibility in plasmid production
  • Optimizing plasmid transfection-based production of AAV in suspension culture using single-use bioreactors
  • Implementing scalable and robust technologies based on filtration and chromatography for efficient purification of biologically active AAV
  • Novel Fibro chromatography for plasmid purification and AAV capture.
Presenter
Dr Henrik Ihre
Director Strategic Technologies
Cytiva
View Biography
Presenter
Dr Mats Lundgren
Customer Applications Director, Life Sciences
Cytiva
View Biography
Presenter
Dr Peter Guterstam
Product Manager, Next Generation Resins & Technologies
Cytiva
View Biography
Presenter
Elisa Manzotti
CEO and Founder
BioInsights Publishing
View Biography

Registration Details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)

Submit